Profile of teriparatide in the management of postmenopausal osteoporosis
Andrea Sikon1, Pelin Batur21Cleveland Clinic Lerner COM, Cleveland Clinic, Cleveland, OH, USA; 2Cleveland Clinic Lerner COM, Cleveland Clinic Independence, Independence, OH, USAAbstract: One out of every 2 women within postmenopause are at risk of fracture due to osteoporosis. Fortunately, a growing...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2010-03-01
|
Series: | International Journal of Women's Health |
Online Access: | http://www.dovepress.com/profile-of-teriparatide-in-the-management-of-postmenopausal-osteoporos-a4179 |
id |
doaj-a67b262c5a624014a049da29addddef4 |
---|---|
record_format |
Article |
spelling |
doaj-a67b262c5a624014a049da29addddef42020-11-24T22:17:17ZengDove Medical PressInternational Journal of Women's Health1179-14112010-03-012010default3744Profile of teriparatide in the management of postmenopausal osteoporosisAndrea SikonPelin BaturAndrea Sikon1, Pelin Batur21Cleveland Clinic Lerner COM, Cleveland Clinic, Cleveland, OH, USA; 2Cleveland Clinic Lerner COM, Cleveland Clinic Independence, Independence, OH, USAAbstract: One out of every 2 women within postmenopause are at risk of fracture due to osteoporosis. Fortunately, a growing arsenal of therapies is becoming available to treat this disease and prevent fracture. A new class of anabolic agents has emerged within the last decade that brought with it a new concept in osteoporosis therapy: building new stronger bone rather than simply inhibiting bone turnover. Evidence is accumulating to understand how to best utilize these new agents, and which patients benefit most. This article will review the effectiveness, risks, timing and clinical uses of teriparatide in postmenopausal osteoporosis.Keywords: osteoporosis, menopause, teriparatide http://www.dovepress.com/profile-of-teriparatide-in-the-management-of-postmenopausal-osteoporos-a4179 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Andrea Sikon Pelin Batur |
spellingShingle |
Andrea Sikon Pelin Batur Profile of teriparatide in the management of postmenopausal osteoporosis International Journal of Women's Health |
author_facet |
Andrea Sikon Pelin Batur |
author_sort |
Andrea Sikon |
title |
Profile of teriparatide in the management of postmenopausal osteoporosis |
title_short |
Profile of teriparatide in the management of postmenopausal osteoporosis |
title_full |
Profile of teriparatide in the management of postmenopausal osteoporosis |
title_fullStr |
Profile of teriparatide in the management of postmenopausal osteoporosis |
title_full_unstemmed |
Profile of teriparatide in the management of postmenopausal osteoporosis |
title_sort |
profile of teriparatide in the management of postmenopausal osteoporosis |
publisher |
Dove Medical Press |
series |
International Journal of Women's Health |
issn |
1179-1411 |
publishDate |
2010-03-01 |
description |
Andrea Sikon1, Pelin Batur21Cleveland Clinic Lerner COM, Cleveland Clinic, Cleveland, OH, USA; 2Cleveland Clinic Lerner COM, Cleveland Clinic Independence, Independence, OH, USAAbstract: One out of every 2 women within postmenopause are at risk of fracture due to osteoporosis. Fortunately, a growing arsenal of therapies is becoming available to treat this disease and prevent fracture. A new class of anabolic agents has emerged within the last decade that brought with it a new concept in osteoporosis therapy: building new stronger bone rather than simply inhibiting bone turnover. Evidence is accumulating to understand how to best utilize these new agents, and which patients benefit most. This article will review the effectiveness, risks, timing and clinical uses of teriparatide in postmenopausal osteoporosis.Keywords: osteoporosis, menopause, teriparatide |
url |
http://www.dovepress.com/profile-of-teriparatide-in-the-management-of-postmenopausal-osteoporos-a4179 |
work_keys_str_mv |
AT andreasikon profileofteriparatideinthemanagementofpostmenopausalosteoporosis AT pelinbatur profileofteriparatideinthemanagementofpostmenopausalosteoporosis |
_version_ |
1725785634809839616 |